ArticleScientific reports2026
Pathogenic mechanism of the PLS1 gene variant in hearing loss and functional validation in a zebrafish model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PLS1, encoding an actin-bundling protein Plastin 1, is one of the pathogenic genes responsible for autosomal dominant non-syndromic hearing loss. The cellular damage caused by mutant plastin proteins may arise from loss of function and/or dominant-negative effects. In this study, we investigated the pathogenic mechanism of PLS1 mutations by establishing both in vitro cellular models and in vivo zebrafish models. Immunoprecipitation demonstrated that the ΔExon8 mutation disrupts the intramolecular interaction between the ABD1 and ABD2 domains, while immunofluorescence colocalization revealed that the mutation alters the binding pattern of PLS1 to actin bundles and disturbs cytoskeletal organization. Through zebrafish FM1-43 uptake assays, we showed that the mutant protein impaired the functional opening and permeability of the stereociliary mechanoelectrical transduction (MET) channel. Although both PLS1-knockout zebrafish and zebrafish expressing ΔExon8-PLS1 exhibited behavioral signs of hearing impairment, defects in MET channel uptake were observed only in the mutant-expressing fish. Notably, neither PLS1 deficiency nor re-expression of human wild-type PLS1 in knockout zebrafish reproduces this MET defect. Thus, the mutation not only reduces native PLS1 function but also interferes with normal MET channel activity. In summary, our findings indicate that the DFNA76 phenotype caused by the PLS1ΔExon8 mutation is likely due to a dominant-negative effect with partial loss-of-function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.